Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival

Z Gastroenterol 2025; 63(08): e454-e455
DOI: 10.1055/s-0045-1810775

Abstracts | DGVS/DGAV

Kurzvorträge

Autoimmune und cholestatische Lebererkrankungen: neue Wege in der Behandlung Freitag, 19. September 2025, 14:45 – 16:21, Seminarraum 14 + 15

Authors

B E Hansen

¹Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Kanada

²Department of Epidemiology, Erasmus MC, Rotterdam, Niederlande

³Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Kanada
A Teufel

⁴Section Hepatology, Section Clinical Bioinformatics, University Medical Centre Mannheim, Mannheim, Deutschland
S Carroll

⁵Gilead Sciences, Inc., Foster City, Vereinigte Staaten
Y Zhou

⁵Gilead Sciences, Inc., Foster City, Vereinigte Staaten
C F Murillo Perez

⁵Gilead Sciences, Inc., Foster City, Vereinigte Staaten
G M Hirschfield

¹Division of Gastroenterology and Hepatology, Toronto Centre for Liver Disease, University of Toronto, Toronto, Kanada